Conserved induction of distinct antiviral signalling kinetics by primate interferon lambda 4 proteins
C. Guo, D. Reuss, J. D. Coey, S. Sukumar, B. Lang, J. McLauchlan, S. Boulant, M. L. Stanifer, C. Bamford
Abstract
Interferon lambdas (IFN{lambda}) (also known as type III IFNs) are critical cytokines that combat infection predominantly at barrier tissues, such as the lung, liver and gastrointestinal tract. Humans have four IFN{lambda}s (1-4) where IFN{lambda}1-3 show [~]80-95% homology and IFN{lambda}4 is the most divergent displaying only [~]30% sequence identity. Variants in IFN{lambda}4 in humans are associated with the outcome of infection, such as with hepatitis C virus. However, how IFN{lambda}4 variants impact cytokine signalling in other tissues and how well this is conserved is largely unknown. In this study we address whether differences in antiviral signalling exist between IFN{lambda}4 variants in human hepatocyte and intestinal cells, comparing them to IFN{lambda}3. We demonstrate that compared to IFN{lambda}3, wild-type human IFN{lambda}4 induces a signalling response with distinct magnitudes and kinetics, which is modified by naturally-occurring variants P70S and K154E in both cell types. IFN{lambda}4s distinct antiviral response was more rapid yet transient compared to IFN{lambda}1 and 3. Additionally, divergent antiviral kinetics were also observed using non-human primate IFN{lambda}s and cell lines. Furthermore, an IFN{lambda}4-like receptor-interacting interface failed to alter IFN{lambda}1s kinetics. Together our data provide further evidence that major functional differences exist within the IFN{lambda} gene family. These results highlight the possible tissue specialisation of IFN{lambda}s and encourage further investigation of the divergent, non-redundant activities of IFN{lambda}4 and other IFN{lambda}s. Contribution to the FieldViral infections remain major causes of death and disease in humans and other animals. Interferons (IFNs) are a diverse group of host signalling proteins that can induce a potent antiviral state in cells and are intimately involved in the outcome of infection. Genetic variants within one IFN (interferon lambda 4, IFN{lambda}4) are associated with the outcome of hepatitis C infection in humans. However, how IFN{lambda}4 functions - and how natural variants affect its activity - remains poorly understood. Comparing how the antiviral activity changes over time following stimulation with different IFN{lambda}s, we identified that IFN{lambda}4 induces a more rapid antiviral state compared to other IFN{lambda}s in liver and intestinal cells. Importantly, this response was conserved within human variants and between humans and non-human primates (chimpanzee and Rhesus macaque). Our results shed light on the unique functions of the divergent IFN{lambda}4 protein.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A Polymorphic Residue That Attenuates the Antiviral Potential of Interferon Lambda 4 in Hominid Lineages
C. G. G. Bamford, E. Aranday-Cortes, … J. McLauchlan·bioRxiv·Mar 26, 2018
- Interferon lambda 4 impacts broadly on hepatitis C virus diversity.
M. Azim Ansari, Elihú Aranday-Cortés, … Vincent Pedergnana·bioRxiv·Apr 20, 2018
- Mechanisms of Differential Signal Transduction by IFNLR1 Variants
Laura A. Novotny, Carla Martinez-Morant, … Eric G. Meissner·Journal of Innate ImmunityPeer-reviewed·May 29, 2026
- Differential induction of interferon stimulated genes between type I and type III interferons is independent of interferon receptor abundance
K. Pervolaraki, S. Rastgou Talemi, … S. Boulant·bioRxiv·Oct 19, 2018
- Type III interferons may suppress viral infections by triggering cell death
Wiktor Prus, Frederic Grabowski, … Tomasz Lipniacki B·bioRxiv·Sep 9, 2024
- Kinetics Of Interferon-{lambda} And Receptor Expression In Response To In Vitro Respiratory Viral Infection
A. Lozhkov, N. Yolshin, … A. Vasin·bioRxiv·Dec 30, 2021